Venous and nerve invasion as prognostic factors in postoperative survival of patients with resectable cancer of the rectum

1983 ◽  
Vol 26 (9) ◽  
pp. 613-617 ◽  
Author(s):  
J. B. Knudsen ◽  
Tove Nilsson ◽  
M. Sprechler ◽  
Å. Johansen ◽  
N. Christensen
Keyword(s):  
Prognostic Factors ◽  
Postoperative Survival ◽  
Cancer Of The Rectum ◽  
Nerve Invasion ◽  
Resectable Cancer

scholarly journals Clinicodemographic aspect of resectable pancreatic cancer and prognostic factors for resectable cancer

2012 ◽  
Vol 10 (1) ◽  
pp. 77 ◽  
Author(s):  
Kun-Chun Chiang ◽  
Chun-Nan Yeh ◽  
Shir-Hwa Ueng ◽  
Jun-Te Hsu ◽  
Ta-Sen Yeh ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Prognostic Factors ◽  
Resectable Pancreatic Cancer ◽  
Resectable Cancer

scholarly journals Prognostic factors for postoperative survival among patients with rhabdomyosarcoma of the limbs

2018 ◽  
Vol Volume 10 ◽  
pp. 4181-4189 ◽  
Author(s):  
Shihong Ren ◽  
Zhan Wang ◽  
Xin Huang ◽  
Lingling Sun ◽  
Jinxiang Shao ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Postoperative Survival

scholarly journals Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis

Cancers ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 1057
Author(s):  
Yuko Mataki ◽  
Hiroshi Kurahara ◽  
Tetsuya Idichi ◽  
Kiyonori Tanoue ◽  
Yuto Hozaka ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factors ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Multidisciplinary Treatment ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Ductal Adenocarcinoma ◽  
Conversion Surgery ◽  
Clinical Benefits ◽  
Resectable Cancer

Background: Unresectable pancreatic ductal adenocarcinoma (UR-PDAC) has a poor prognosis. Conversion surgery is considered a promising strategy for improving the prognosis of UR-PDAC. This study aimed to investigate the clinical benefits of conversion surgery in patients with UR-PDAC. Methods: We retrospectively evaluated patients with PDAC who were referred to our department for possible surgical resection between January 2006 and December 2019. Conversion surgery was performed only in patients with UR-PDAC who could expect R0 resection. We analyzed the prognostic factors for overall survival among patients who underwent conversion surgery. Results: Overall, 638 patients with advanced pancreatic cancer were enrolled in this study. According to resectability, resectable cancer (R) was present in 180 patients, borderline resectable cancer (BR) was present in 60 patients, unresectable locally advanced cancer (UR-LA) was present in 252 patients, and unresectable cancer with distant metastasis (UR-M) was present in 146 patients. Conversion surgery was performed in 20 of the 398 UR cases (5.1%). The median period between the initial therapy and conversion surgery was 15.5 months. According to the Response Evaluation Criteria in Solid Tumors (RECIST) evaluation, the treatment response was CR in one patient, PR in 13, SD in five, and PD in one. Downstaging was pathologically determined in all cases. According to the Evans grading system, grade I was observed in four patients (20%), grade IIb was observed in seven (35%), III was observed in seven (35%), and IV was observed in two (10%). We compared the overall survival period from initial treatment among patients undergoing conversion surgery; the median overall survival durations in the conversion surgery, R, BR, UR-LA, and UR-M groups were 73.7, 32.7, 22.7, 15.7, and 8.8 months, respectively. Multivariate analysis revealed that the presence or absence of chemoradiotherapy (CRT) and the RECIST partial response (PR)/complete response (CR) for the main tumor were statistically significant prognostic factors for overall survival among patients undergoing conversion surgery (p = 0.004 and 0.03, respectively). Conclusion: In UR-PDAC, it is important to perform multidisciplinary treatment, including CRT with conversion surgery.

scholarly journals Clinical Benefits of Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma: A Single-Institution, Retrospective Analysis

2021 ◽  
Author(s):  
Yuko Mataki ◽  
Hiroshi Kurahara ◽  
Tetsuya Idichi ◽  
Kiyonori Tanoue ◽  
Yuto Hozaka ◽  
...  
Keyword(s):  
Overall Survival ◽  
Prognostic Factors ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Multidisciplinary Treatment ◽  
Locally Advanced ◽  
Advanced Pancreatic Cancer ◽  
Ductal Adenocarcinoma ◽  
Conversion Surgery ◽  
Clinical Benefits ◽  
Resectable Cancer

BackgroundUnresectable pancreatic ductal adenocarcinoma (UR-PDAC) has a poor prognosis. Conversion surgery is considered a promising strategy for improving the prognosis of UR-PDAC. This study aimed to investigate the clinical benefits of conversion surgery in patients with UR-PDAC.Methods: We retrospectively evaluated patients with PDAC who were referred to our department for possible surgical resection between January 2006 and December 2019. Conversion surgery was performed only in patients with UR-PDAC who could expect R0 resection. We analyzed the prognostic factors for overall survival among patients who underwent conversion surgery. Results: Overall, 638 patients with advanced pancreatic cancer were enrolled in this study. According to resectability, resectable cancer (R) was present in 180 patients, borderline resectable cancer (BR) in 60, unresectable locally advanced cancer (UR-LA) in 252, and unresectable cancer with distant metastasis (UR-M) in 146. Conversion surgery was performed in 20 of the 398 UR cases (5.1%). The median period between the initial therapy and conversion surgery was 15.5 months. According to the RECIST evaluation, the treatment response was CR in one patient, PR in 13, SD in five, and PD in one. Downstaging was pathologically determined in all cases. According to the Evans grading system, grade I was observed in four patients (20%), grade IIb in seven (35%), III in seven (35%), and IV in two (10%). We compared the overall survival period from initial treatment among patients undergoing conversion surgery; the median overall survival durations in the conversion surgery, R, BR, UR-LA, and UR-M groups were 73.7, 32.7, 22.7, 15.7, and 8.8 months, respectively. Multivariate analysis revealed that the presence or absence of CRT and the RECIST PR/CR for the main tumor were statistically significant prognostic factors for overall survival among patients undergoing conversion surgery (p = 0.004 and 0.03, respectively).Conclusion: In UR-PDAC, it is important to perform multidisciplinary treatment, including CRT with conversion surgery.

Prognostic Factors in Adult Medulloblastoma. A Clinico-Pathologic Study

1995 ◽  
Vol 81 (5) ◽  
pp. 338-346 ◽  
Author(s):  
Maria Teresa Giordana ◽  
Paola Cavalla ◽  
Adriano Chiò ◽  
Silvia Marino ◽  
Riccardo Soffietti ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Survival Rates ◽  
General Assumption ◽  
Adult Patients ◽  
Postoperative Survival ◽  
Nuclear Antigen ◽  
Ki 67 ◽  
Adult Medulloblastoma ◽  
Microscopic Features ◽  
Mib 1

Aims and background. Medulloblastoma in adults is a rare tumor. The small number of cases in the reported series has not permitted a definite assessment of the prognostic role of clinical, pathologic and cell kinetics factors. The largest series of medulloblastoma in adults treated in a single institution is herein reported. Methods. The clinical, therapeutic, pathologic and proliferation features of medulloblastoma in 44 adult patients (> 18 years) were analyzed retrospectively with regard to postoperative survival. The proliferation potential of each tumor was evaluated by the immunohistochemical demonstration of proliferating cell nuclear antigen (PCNA) and Ki-67, clone MIB-1, in paraffin sections. Results. The overall 5- and 10-year survival rates were 40% and 35.6%, respectively. Significant factors in predicting a longer postoperative survival were: age < 37 years, decade of management (1977-1990), radiotherapy (50-55 Gy on the posterior fossa and 30-35 Gy on the spinal cord) and nuclear isomorphism. When corrected for adequacy of radiotreatment, desmoplastic type and differentiation were significantly correlated with a shorter survival. The PCNA-labelling index (LI) ranged from 34.5 to 82.2%, the MIB-1-LI ranged from 9.6 to 64.7%. No association was found between PCNA- or MIB-1-LI values and microscopic features, or between LI values and prognosis. Conclusions. Contrary to a general assumption, desmoplastic medulloblastoma and differentiated medulloblastoma are negative prognostic factors in adequately radiotreated adult patients. This may possibly be referred to lower radiosensitivity of these tumor variants. The LI with PCNA or Ki-67 is of no help in identifying aggressive tumors.

Sign in / Sign up

Export Citation Format

Share Document